Onco Wiki / Krankheit

Wesentliche Thrombozytämie

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDDIS-ET
ArtErkrankung
Aliase
ETGrundlegende ThrombozytämiePrimäre ThrombozytämieЕсенціальна тромбоцитемія
Statusreviewed 2026-04-25 | pending_clinical_signoff
ErkrankungenNone declared
QuellenSRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Quelle: YAML

icd_o_3_morphology9962/3
icd_o_3_topography["C42.1"]
icd_10D47.3
who_classificationGrundlegende Thrombozytämie (ET) — Ph-negative myeloproliferative Neoplasma (pro WHO 5.

Fähigkeiten

Anmerkungen

Authored as separate disease from PV (see DIS-PV.notes for rationale). Treatment: low-risk ET → ASA only (avoid in extreme thrombocytosis with acquired vWD); high-risk → HU 1L; anagrelide 2L (PT-1 trial — non-inferior on thrombosis but more arterial events + bleeding + MF progression). PreT-PMF ("prefibrotic primary myelofibrosis") is increasingly distinguished from ET on trephine — has worse prognosis and behaves more like PMF; current scope: standard ET only. STUB — requires clinical co-lead signoff before publication. Myeloid expansion (heme).

Verwendet von

Therapeutische Relevanz

Algorithmen

Erkrankung

Anwendungsgebiet

Fragebogen

Warnhinweis

Quellen